SELECTION OF EXCIPIENTS IN THE DEVELOPMENT OF TECHNOLOGY FOR ANTISPASMODIC TABLETS

Admin bo'lib kirish (www.admin.slib.uz)

Tizim sinov (TEST) rejimida ishlamoqda! Murojat uchun @slib_support

Eski talqinga o'tish link

12 июн 2025

Asosiy til:Ingliz

SELECTION OF EXCIPIENTS IN THE DEVELOPMENT OF TECHNOLOGY FOR ANTISPASMODIC TABLETS

Fan yo'nalishi:

684ac3b0ab4aa.pdf

PDF

Eurasian Journal of Medical and Natural Sciences

Maqola chop etish see more

MAQOLA ANNOTATSIYASI

The development of antispasmodic tablets requires careful selection of excipients to ensure the tablets' efficacy, stability, and patient compliance. Excipients, which play a crucial role in the formulation of pharmaceutical dosage forms, are non-active ingredients that aid in the manufacturing process and enhance the performance of the active pharmaceutical ingredient (API). In this study, various excipients commonly used in antispasmodic tablet formulations, including binders, disintegrants, lubricants, and stabilizers, were evaluated based on their physicochemical properties and compatibility with the active ingredients. The selection criteria for excipients included their ability to improve the dissolution rate, bioavailability, and stability of the tablets, while minimizing side effects. The influence of these excipients on the mechanical properties and release profile of the tablets was assessed through various in vitro tests. The study highlights the importance of excipient selection in optimizing the formulation and ensuring the desired therapeutic outcomes for patients with gastrointestinal disorders

MUALIFLAR

Teglar

# stability# bioavailability# excipients# dissolution rate# lubricants# disintegrants# antispasmodic tablets# formulation technology# pharmaceutical dosageforms# binders# stabilizers

Maqolani baholang

0

0 ta

Maqola idintifikatorlari

ROI:

https://eroi.uz/11.0201/A0625-0085

DOI:

Mavjud emas

Foydalanilgan adabiyotlar

1.Patil, P. A., & Rathi, M. V. (2019). Formulation and biopharmaceutical evaluation of antispasmodic tablets. Journal of Pharmaceutical Science and Research, 11(5), 1323-1330.2.Singh, A., & Gupta, S. (2020). Pharmacokinetics and bioavailability of antispasmodic agents in gastrointestinal disorders. European Journal of Clinical Pharmacology, 76(8), 1021-1028.3.Almeida, R. M., & Lima, J. S. (2018). Development of novel antispasmodicformulations: Challenges and opportunities. International Journal of Pharmaceutics, 554(1-2), 45-55.4.Khan, M. R., & Ahmed, I. (2021). Comparative study on the pharmacokinetics of antispasmodic tablets: A focus on bioavailability and absorption. Journal ofClinical and Experimental Gastroenterology, 12(3), 220-227.5.Sharma, P., & Rajput, S. (2022). In vitro and in vivo evaluation of antispasmodic tablet formulations. Drug Development and Industrial Pharmacy, 48(10), 1743-1751.6.Niazi, S. K. (2017). Pharmaceutical Dissolution Testing: Antispasmodic Drug Release. CRC Press.7.World Health Organization (WHO). (2016). Pharmaceutical development of antispasmodics for gastrointestinal disorders: WHO guidelines. WHO Press.8.Lohani, S., & Choudhury, H. (2023). Biopharmaceutical properties of gastrointestinal medications: A review of antispasmodic tablets. Drug Development Research, 84(1), 67-78.9.Beyreuther, K., & Walter, M. (2015). Pharmacology of antispasmodics: A review of mechanisms of action. Pharmacological Reviews, 68(2), 457-472.10.Kumari, A., & Mishra, R. (2017). Formulation strategies to improve the bioavailability of antispasmodic drugs. Journal of Drug Delivery Science and Technology, 40, 123-135.